Aquestive Therapeutics, Inc. (AQST) |
|
1.515 0.015 (1%)
|
09-26 15:28 |
|
Open: |
1.5 |
Pre. Close: |
1.5 |
|
High:
|
1.58 |
Low:
|
1.5 |
|
Volume:
|
125,471 |
Market Cap:
|
101(M) |
|
|
|
Technical analysis |
as of: 2023-09-26 2:47:13 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 1.99 One year: 2.17 |
| Support: |
Support1: 1.47 Support2: 1.22 |
| Resistance: |
Resistance1: 1.71 Resistance2: 1.86 |
| Pivot: |
1.58  |
| Moving Average: |
MA(5): 1.59 MA(20): 1.6
MA(100): 1.87 MA(250): 1.32 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 22.4 %D(3): 36.2 |
| RSI: |
RSI(14): 42.3 |
| 52-week: |
High: 2.69 Low: 0.72 |
| Average Vol(K): |
3-Month: 329 (K) 10-Days: 307 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AQST ] has closed above bottom band by 29.9%. Bollinger Bands are 62.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.61 - 1.62 |
1.62 - 1.63 |
|
Low:
|
1.45 - 1.47 |
1.47 - 1.48 |
|
Close:
|
1.48 - 1.5 |
1.5 - 1.52 |
|
Company Description |
|
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly; and AQST-109, an orally delivered epinephrine product candidate for the emergency treatment of allergic reactions, including anaphylaxis. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc. was incorporated in 2004 and is headquartered in Warren, New Jersey. |
Headline News |
Tue, 26 Sep 2023
Abeona Therapeutics Submits BLA for Groundbreaking RDEB ... - Best Stocks
Sat, 23 Sep 2023
Aquestive Therapeutics (NASDAQ:AQST) Stock Rating Reaffirmed ... - MarketBeat
Thu, 21 Sep 2023
Aquestive (AQST) Up on Reaffirming Anaphylm Development Pathway - Nasdaq
Thu, 21 Sep 2023
Should You Buy Aquestive Therapeutics Inc (AQST) Stock on Thursday? - InvestorsObserver
Wed, 20 Sep 2023
Thinking about buying stock in Novo Integrated Sciences, Archer ... - PR Newswire
Wed, 20 Sep 2023
Aquestive Therapeutics Reaffirms Timeline and Pathway for ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
67 (M) |
| Shares Float |
58 (M) |
|
% Held by Insiders
|
5.6 (%) |
|
% Held by Institutions
|
26.7 (%) |
|
Shares Short
|
1,820 (K) |
|
Shares Short P.Month
|
2,050 (K) |
Stock Financials |
|
EPS
|
-0.44 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-1.74 |
|
Profit Margin (%)
|
-48.7 |
|
Operating Margin (%)
|
-61.1 |
|
Return on Assets (ttm)
|
-31.4 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
-0.3 |
|
Gross Profit (p.s.)
|
0.42 |
|
Sales Per Share
|
0.69 |
|
EBITDA (p.s.)
|
-0.4 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
12 (M) |
|
Levered Free Cash Flow
|
-12 (M) |
Stock Valuations |
|
PE Ratio
|
-3.59 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-0.9 |
|
Price to Sales
|
2.21 |
|
Price to Cash Flow
|
8.45 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
